WaveMan
WaveMan · Company
ZNTL · Zentalis Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ZNTL Zentalis Pharmaceuticals (ZNTL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001725160
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
63
13F, latest reported quarter

What the filings say about ZNTL

Insiders, 180 days
+$15.2M net bought
1 buyer

Zentalis Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Zentalis Pharmaceuticals, Inc. insiders bought a net $15.2M of stock across 306 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
WALTERS GROUP
BUY
2026-08-19 SECtraded 2026-08-14
4,335,000
$15.2M
-48.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 24.3% of the 17,844,973 shares held after it.
  • No other insider bought within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider WALTERS GROUP bought about $15.2M of ZNTL on Aug 14, 2026, the largest insider purchase at the company since 2023; 63 funds added in the latest 13F quarter.
Vultaggio Vincent
PAO and PFO
SELL
2026-02-10 SEC
6,894
$16.7K
-18.5%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 9, 2026.
  • The trade is 4.7% of the 146,506 shares held after it.
  • 2 other insiders sold within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PAO and PFO Vultaggio Vincent sold about $16.7K of ZNTL on Feb 10, 2026; 2 other insiders sold within 30 days and 63 funds added in the latest 13F quarter.
Bruns Ingmar
Chief Medical Officer
SELL
2026-02-10 SECtraded 2026-02-09
335
$801
-18.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Feb 6, 2026.
  • The trade is 1.0% of the 33,332 shares held after it.
  • 2 other insiders sold within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Bruns Ingmar sold about $801 of ZNTL on Feb 9, 2026; 2 other insiders sold within 30 days and 63 funds added in the latest 13F quarter.
Vultaggio Vincent
PAO and PFO
SELL
2026-02-10 SECtraded 2026-02-09
3,379
$8.1K
-18.5%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Feb 6, 2026.
  • The trade is 2.2% of the 153,400 shares held after it.
  • 2 other insiders sold within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PAO and PFO Vultaggio Vincent sold about $8.1K of ZNTL on Feb 9, 2026; 2 other insiders sold within 30 days and 63 funds added in the latest 13F quarter.
EASTLAND JULIA MARIE
CEO & President
SELL
2026-02-10 SECtraded 2026-02-09
889
$2.1K
-18.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Feb 6, 2026.
  • The trade is 1.1% of the 79,133 shares held after it.
  • 2 other insiders sold within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & President EASTLAND JULIA MARIE sold about $2.1K of ZNTL on Feb 9, 2026; 2 other insiders sold within 30 days and 63 funds added in the latest 13F quarter.
306 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 301 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$15.2M over 180 days
+$15.2M over 90 days · +$15.2M of it by a 10%+ holder
more than 96% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
63 funds bought in last quarter
more than 52% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
$10.0M repurchased, FY to 2025-12-31
below 70% of Pharma & Biotech
Short interest
10.5% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
more than 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ZNTL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.7%12M
-22%+86%+195%+303%2025-102025-122026-022026-042026-062026-082026-10 2026-08-14 · WALTERS GROUP bought $15.2M2025-12-15 · GOEL DAVID E. sold $10.0M2025-12-31 · WALTERS WILLIAM THURMAN bought $7.8M2026-02-06 · Vultaggio Vincent sold $72.8K2026-02-06 · EASTLAND JULIA MARIE sold $19.1K2026-02-10 · Vultaggio Vincent sold $16.7K2026-02-09 · Vultaggio Vincent sold $8.1K2026-02-06 · Bruns Ingmar sold $7.2K2026-02-02 · Vultaggio Vincent sold $6.5K2026-02-09 · EASTLAND JULIA MARIE sold $2.1K2026-02-03 · Vultaggio Vincent sold $1.4K2026-02-09 · Bruns Ingmar sold $801
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ZNTL: institutional holders (13F)

13F holdings, latest reported quarter
5AM Venture Management, LLC
3,947,913 sh
$19.1M
BlackRock, Inc.
3,753,525 sh
$18.2M
Squadron Capital Management LLC
3,700,000 sh
$17.9M
TWO SIGMA INVESTMENTS, LP
3,024,936 sh
$14.7M
VANGUARD CAPITAL MANAGEMENT LLC
2,835,669 sh
$13.8M

Congress trades in ZNTL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ZNTL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ZNTL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$374.9K position · as of 2026-06-30
0.3%
Federated Hermes MDT Small Cap Core ETF
$317.4K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$801.7K position · as of 2026-06-30
0.1%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND
$1.6M position · as of 2026-06-30
0.0%
PRIMECAP Odyssey Aggressive Growth Fund
$3.2M position · as of 2026-07-31
0.0%
VIP Disciplined Small Cap Portfolio
$207.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Eastland
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.3M
n/a
$1.4M
-93%
n/a
2023
$12.9M
n/a
$5.6M
-25%
n/a
2021
$5.9M
n/a
$2.0M
+262%
+42%
2020
$15.0M
n/a
$6.4M
+123%
+42%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $15.2M bought by insiders over 180 days, 63 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ZNTL financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-01-01 to 2025-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$128.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-66.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-49.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-62.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-90.3%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$67.4M$0$0
Operating income-$152.8M-$191.2M-$299.5M-$227.3M
Net income-$137.1M-$165.9M-$292.3M-$236.8M
EPS (diluted)-1.91-2.33-4.47-4.48
Operating cash flow-$125.2M-$170.9M-$207.8M-$163.8M
Cash$36.0M$33.9M$28.0M$43.1M
Buybacks$10.0M$0$0n/a
SEC XBRL, fiscal years, as known on 2026-10-28

ZNTL Stock Sonar score 5/7 axes

Find similar shapesCompare

ZNTL ranks highest on insider conviction (76th percentile) and risk and compliance (59th), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
43
Inputs
  • Return on equity-66.7% · 44 pct, sector of 545
  • Return on assets-49.2% · 45 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-62.6% · 41 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$15.2M · 96 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
52
Inputs
  • Funds adding, latest quarter63 · 52 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
59
Inputs
  • Short interest, % of float+10.5% · 38 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.5% · 81 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ZNTL filings, in plain words

Are Zentalis Pharmaceuticals insiders buying or selling ZNTL?

In the 180 days to 2026-10-28, Zentalis Pharmaceuticals insiders were net buyers, a net $15.2M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Zentalis Pharmaceuticals insiders were net buyers of ZNTL, a net $15.2M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $15.2M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies